Drug class
The phrase "Antineoplastic-Fibroblast Growth Factor Receptor (FGFR) Inh." is a standard compendial and formulary classification representing antineoplastic fibroblast growth factor receptor inhibitors. Read more about Antineoplastic-Fibroblast Growth Factor Receptor (FGFR) Inh.
3 drugs in this class 3 manufacturers
The phrase "Antineoplastic-Fibroblast Growth Factor Receptor (FGFR) Inh." is a standard compendial and formulary classification representing antineoplastic fibroblast growth factor receptor inhibitors.
This therapeutic class comprises targeted small-molecule kinase inhibitors that block aberrant intracellular signaling mediated by the FGFR family of receptor tyrosine kinases, thereby suppressing downstream pathways such as MAPK/ERK and PI3K/AKT that drive malignant cell proliferation and survival.
Agents within this class, including erdafitinib and futibatinib, are primarily indicated for treating locally advanced or metastatic solid tumors harboring susceptible FGFR genetic alterations, most notably urothelial carcinoma and intrahepatic cholangiocarcinoma.
The phrase "Antineoplastic-Fibroblast Growth Factor Receptor (FGFR) Inh." is a standard compendial and formulary classification representing antineoplastic fibroblast growth factor receptor inhibitors
The phrase "Antineoplastic-Fibroblast Growth Factor Receptor (FGFR) Inh." is a standard compendial and formulary classification representing antineoplastic fibroblast growth factor receptor inhibitors
This therapeutic class comprises targeted small-molecule kinase inhibitors that block aberrant intracellular signaling mediated by the FGFR family of receptor tyrosine kinases, thereby suppressing downstream pathways such as MAPK/ERK and PI3K/AKT that drive malignant cell proliferation and survival Agents within this class, including erdafitinib and futibatinib, are primarily indicated for treating locally advanced or metastatic solid tumors harboring susceptible FGFR genetic alterations, most n...
This therapeutic class comprises targeted small-molecule kinase inhibitors that block aberrant intracellular signaling mediated by the FGFR family of receptor tyrosine kinases, thereby suppressing downstream pathways such as MAPK/ERK and PI3K/AKT that drive malignant cell proliferation and survival
Agents within this class, including erdafitinib and futibatinib, are primarily indicated for treating locally advanced or metastatic solid tumors harboring susceptible FGFR genetic alterations, most notably urothelial carcinoma and intrahepatic cholangiocarcinoma
Agents within this class, including erdafitinib and futibatinib, are primarily indicated for treating locally advanced or metastatic solid tumors harboring susceptible FGFR genetic alterations, most notably urothelial carcinoma and intrahepatic cholangiocarcinoma
Following a drug class requires a free Physicians Office Resource account.
